Targeting histone demethylases in cancer therapy

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7111-7113

  Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME; ENZYME INHIBITOR; HISTONE DEMETHYLASE; HISTONE DEMETHYLASE INHIBITOR; HYPOMETHYLATING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; COLON TUMOR; DEMETHYLATION; DRUG POTENTIATION; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NOTE; PRIORITY JOURNAL;

AMINES; ANTINEOPLASTIC AGENTS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; HISTONE DEMETHYLASES; HISTONES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 73149117308     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2399     Document Type: Note

References (11)

1. Huang Y, Murray Stewart T, Wu Y, et al. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 2009;15:7217-28.
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92.
3. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-80.
4. Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003;63:7089-93.
5. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-9.
6. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 2007;8:307-18.
7. Shi Y, Whetstine JR. Dynamic regulation of histone lysine methylation by demethylases. Mol Cell 2007;25:1-14.
8. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;411:349-54.
9. Cihak A, Vesely J, Skoda J. Azapyrimidine nucleosides: metabolism and inhibitory mechanisms. Adv Enzyme Regul 1985;24:335-54.
10. Polo JM, Dell'Oso T, Ranuncolo SM, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 2004;10:1329-35.
11. Fiskus W, Wang Y, Sreekumar A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009;114:2733-43.